Interim Report First Half Year 2024, 1 January – 30 June 2024
Read the report PDF (in English) here
MEET US AT:
Meet us here
Meet us here
Meet us here
Meet us here
Meet us here
Meet us here
Meet us here
Meet us here
Meet us here
Meet us here
ARTICLES:
2. analyse – Pila Pharma Halvårsrapport 2024 (September 30, 2024)
Read the report PDF (in Danish) here
Read the report (in Swedish) here
Read the report PDF (in Danish) here
Read the report (in English) here
PRESENTATIONS AND INTERVIEWS:
PILA PHARMA x REDEYE H1 Report & Q&A [August 29, 2024]
PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Investor Forum with Redeye and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Einarsson, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovasculardisease that PILA aims to tap into.
The presentation & Q&A is conducted (in English) here
PILA PHARMA x AKTIESPARARNA – H1 Report & Q&A [August 28, 2024]
PILA PHARMA’s CEO, Mr. Gustav H. Gram participates in a online Life Science evening with Aktiespararna and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with Analyst Filip Lindkvist, answering investor questions about PILA PHARMA, the market and global trends for Diabetes, Obesity and Cardiovascular disease that PILA aims to tap into.
The presentation & Q&A is conducted (in English) here
PILA PHARMA x Stokk.io – H1 Report & Q&A [August 27, 2024]
PILA PHARMA’s CEO, Mr. Gustav H. Gram hosts a webinar with Stokk.io and provides an update on the Company’s H1 report, the happenings and expected events for H2, 2024. Furthermore we have a Q&A with investor questions about PILA PHARMA. In this questions about the market and global trends for Diabetes, obesity and cardiovascular disease that PILA aims to tap into are answer.
The presentation & Q&A is conducted (in English) here
International Diabetes & Nutrition Symposia, June 29th
Founder, Inventor, CSO and Chairman of PILA PHARMA, Dr. Dorte X. Gram presents the short PILA PHARMA story and rationale behind treatment of metabolic conditions with a TRPV1 / Capsaicin receptor antagonist, to the DNSG 2024 Symposium, the 41st International Symposium on Diabetes and Nutrition, which took place in Uppsala, Sweden on June 27th – 30th, 2024.
Please, find the link to the video (in English) here
The CEO of Pila Pharma was recently interviewed by Vækstaktier, Denmark about his participation in BIO INTERNATIONAL CONVENTION 2024, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe.
Find the link to the article and other articles about Pila Pharma (in Danish) on Vækstaktier.dk
Aktiespararna June 12th, 2024
PILA PHARMA’s CEO, Mr. Gustav H. Gram presents the company.
Please, find the link to the video (in English) here
Pila Pharma Redeye Diabetes Day May 23rd, 2024
PILA PHARMA’s CEO, Mr. Gustav H. Gram provides an insight into the market and global trends for Diabetes, obesity and cardiovascular disease that PILA aims to tap into. The presentation and Q&A is conducted in English.
Please, find the link to the video (in English) here
Stokk.io April 22nd, 2024
Newly appointed CEO, Gustav H. Gram, hosts a Q&A with Stokk.io on PILA PHARMA’s changes with Founder Dorte X. Gram transitioning to Chairman of the Board and what changes and direction that investors can expect. The Q&A is conducted in English together with Anders Egsvang from Stokk.io
Please, find the link to the video (in English) here
We were incredibly honoured that the American Diabetes Association(ADA) featured PILA PHARMA AB in the Thought Leadership Film Series, a part of ADA’s 81st Scientific Sessions program in June 2021, starting today.
In the invitation letter, it was written: We are interested in profiling Pila’s pioneering research and development in the science surrounding TPRV1 inhibition, and how regulation of this mechanism has tremendous potential to be exploited for the treatment of diabetes.
Thank you so much to our scientific advisors Mark Evans and Jens Juul Holst for helping our previous CEO explain!
Watch the video (in English) here
